Pharmacogenomics and adverse drug reactions

Shashi Amur, Issam Zineh, Darrell R. Abernethy, Shiew Mei Huang, Lawrence J. Lesko

Research output: Contribution to journalArticlepeer-review

Abstract

Adverse drug reactions (ADRs) observed during drug development have been the cause for discontinuing development of many drugs. In addition, serious but rare ADRs observed after marketing have led to withdrawal of some drugs. A priori identification of individuals at risk of developing ADRs for a given drug will help develop strategies to reduce the risk for ADRs in these patients. US FDA initiatives and efforts at reducing ADRs to make drugs safer are described, including updating of drug labels to include genomic information intended to reduce ADRs. Pharmacogenomics can also be harnessed to identify individuals at risk of developing serious ADRs and to treat these individuals with alternative therapy, thus converting ADRs that are traditionally considered unavoidable to avoidable ADRs.

Original languageEnglish (US)
Pages (from-to)633-642
Number of pages10
JournalPersonalized Medicine
Volume7
Issue number6
DOIs
StatePublished - Nov 1 2010

Keywords

  • CYP
  • adverse drug reaction
  • drug label
  • drug safety
  • drug-metabolizing enzymes
  • genetic
  • genomic
  • polymorphism
  • variant

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Fingerprint

Dive into the research topics of 'Pharmacogenomics and adverse drug reactions'. Together they form a unique fingerprint.

Cite this